{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-345753","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2026-08-12T11:35:26+00:00","discovered_at":"2026-08-12T11:40:00.597765+00:00","generated_at":"2026-08-12T11:40:05.843549+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xilio reports Q2 2026 results; FDA clears IND for XTX501 bispecific PD-1/masked IL-2","bullets":["FDA cleared IND for XTX501 (bispecific PD-1/masked IL-2); Phase 1/2 dosing expected 2H 2026 in NSCLC and solid tumors; initial data 2H 2027.","Cash and equivalents $136.0M at 6/30/26 vs $137.5M at 12/31/25; runway into Q1 2028 (excl. warrant proceeds and milestones).","Q2 2026 collaboration revenue $18.7M vs $8.1M YoY; net loss $6.4M vs $15.8M YoY.","IND-enabling studies for masked TCEs targeting CLDN18.2 and PSMA+STEAP1; INDs planned 2H 2027.","Appointed Ben Harshbarger as Chief Legal Officer in June 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-345753","json":"https://secwatch.observer/filing/0001193125-26-345753.json","markdown":"https://secwatch.observer/filing/0001193125-26-345753.md","text":"https://secwatch.observer/filing/0001193125-26-345753.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526345753/0001193125-26-345753-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526345753/xlo-20260812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T11:40:05.843549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}